Blindedness in clinical trials of therapies for rheumatoid arthritis: comment on the article by Bresnihan et al.
Epstein
W V
WV
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D004311:Double-Blind Method; D006801:Humans; D010919:Placebos; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D010919:Placebos; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins